-
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
HOVON CLL Working Group, 28 Sept 2023, In: Blood. 142, 13, p. 1131-1142 12 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial
Groen, K., Stege, C. A. M., Nasserinejad, K., de Heer, K., van Kampen, R. J. W., Leys, R. B. L., Thielen, N., Westerman, M., Wu, K-L., Ludwig, I., Issa, D. E., Velders, G. A., Vekemans, M-C., Timmers, G-J., de Boer, F., Tick, L. W., Verbrugge, A., Buitenhuis, D., Cunha, S. M., van der Spek, E., & 9 others , 1 Sept 2023, In: EClinicalMedicine. 63, 102167.Research output: Contribution to journal › Article › Academic › peer-review
-
Treatment of older patients with multiple myeloma: towards a frailty approach
Stege, C. A. M., 16 Feb 2023, s.l.: Ridderprint. 282 p.Research output: PhD Thesis › Phd-Thesis - Research and graduation internal
- All publications